427 related articles for article (PubMed ID: 20941455)
1. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
Huang J; Cao Y; Liao C; Wu L; Gao F
Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
[TBL] [Abstract][Full Text] [Related]
2. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
4. Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Li XM; Sun SG; Zhang WD
Chin Med J (Engl); 2012 Jul; 125(13):2339-45. PubMed ID: 22882859
[TBL] [Abstract][Full Text] [Related]
5. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
6. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ
N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123
[TBL] [Abstract][Full Text] [Related]
7. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
[TBL] [Abstract][Full Text] [Related]
9. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
10. Apixaban. After hip or knee replacement: LMWH remains the standard treatment.
Prescrire Int; 2012 Sep; 21(130):201-2, 204. PubMed ID: 23016247
[TBL] [Abstract][Full Text] [Related]
11. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
12. The role of apixaban for venous and arterial thromboembolic disease.
Prom R; Spinler SA
Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
15. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
King DA; Pow RE; Dickison DM; Vale PR
Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
[TBL] [Abstract][Full Text] [Related]
16. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
[TBL] [Abstract][Full Text] [Related]
17. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
Lassen MR; Gallus A; Raskob GE; Pineo G; Chen D; Ramirez LM;
N Engl J Med; 2010 Dec; 363(26):2487-98. PubMed ID: 21175312
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Martin MT; Nutescu EA
Curr Med Res Opin; 2011 Nov; 27(11):2123-31. PubMed ID: 21942466
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
